BAXTER INTL INC shareholders Q3 2023

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2023
NameSharesValueWeighting ↓
EDMOND DE ROTHSCHILD HOLDING S.A. 1,068,600$40,328,9640.81%
PERKINS CAPITAL MANAGEMENT INC 20,934$7900.78%
Argyle Capital Management Inc. 55,829$2,106,9860.77%
Ridgewood Investments LLC 29,349$1,107,6200.73%
Barbara Oil Co. 40,000$1,509,6000.72%
W.H. Cornerstone Investments Inc. 20,414$7700.68%
Palisade Asset Management, LLC 142,984$5,396,2160.66%
DEPRINCE RACE & ZOLLO INC 702,234$26,502,3110.64%
CSU Producer Resources, Inc. 4,400$166,0560.64%
Baron Wealth Management LLC 26,311$992,9770.63%
Adalta Capital Management LLC 24,460$9280.63%
Alyeska Investment Group, L.P. 2,422,122$91,410,8840.62%
DELTA ASSET MANAGEMENT LLC/TN 157,696$5,951,4420.62%
Investment Management Corp of Ontario 408,778$15,427,2820.61%
SAMLYN CAPITAL, LLC 964,141$36,386,6820.60%
BRAUN STACEY ASSOCIATES INC 319,919$12,0740.59%
HOWE & RUSLING INC 131,508$4,963,0970.59%
RIVER GLOBAL INVESTORS LLP 66,114$2,496,1340.58%
Addison Capital Co 19,801$7470.58%
HARRIS ASSOCIATES L P 7,680,385$289,857,7230.56%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2023. To view BAXTER INTL INC's shareholder history, click here.